Drug and Alcohol Dependence
Volume 65, Issue 3 , Pages 283-290 , 1 February 2002

Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis

  • Magı́ Farré

      Affiliations

    • Pharmacology Unit (Institut Municipal d'Investigació Mèdica-IMIM), Carrer Doctor Aiguador 80, E-08003, Barcelona, Spain
    • Universitat Autònoma de Barcelona, Edifici M, 08193 Bellaterra, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34-93-2211-009; fax: +34-93-2211-3237
    • ,
  • Anna Mas

      Affiliations

    • Pharmacology Unit (Institut Municipal d'Investigació Mèdica-IMIM), Carrer Doctor Aiguador 80, E-08003, Barcelona, Spain
    • ,
  • Marta Torrens

      Affiliations

    • Drug Dependence-Psychiatric Research Unit (Hospital del Mar-IMIM), Paseo Marı́timo 25, 08003 Barcelona, Spain
    • ,
  • Vı́ctor Moreno

      Affiliations

    • Unit of Epidemiology (Institut Català d'Oncologia-ICO), Gran Via km 2.7, 08907 Hospitalet de Llobregat, Barcelona, Spain
    • Universitat Autònoma de Barcelona, Edifici M, 08193 Bellaterra, Barcelona, Spain
    • ,
  • Jordi Camı́

      Affiliations

    • Pharmacology Unit (Institut Municipal d'Investigació Mèdica-IMIM), Carrer Doctor Aiguador 80, E-08003, Barcelona, Spain
    • Universitat Pompeu Fabra, Doctor Aiguader 80, 08003 Barcelona, Spain

Received 12 September 2000 ,Accepted 29 May 2001.

References 

  1. Anonymous. Buprénorphine et substitution. Rev. Prescr. 1999;19:102–106
  2. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. J. Am. Med. Ass. 2001;285:45
  3. Banys P, Tusel DJ, Sees KL, Reilly PM, Delucchi LL. Low (40 mg) versus high (80 mg) dose methadone in a 180-day heroin detoxification programme. J. Subst. Abuse Treatment. 1994;11:225–232
  4. Cooper JR. Ineffective use of psychoactive drugs. Methadone treatment is no exception. J. Am. Med. Ass. 1992;267:281–282
  5. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Psychiat. 1977;60:537–545
  6. D'Aunno T, Vaughn TE. Variation in methadone treatment practices: results from a national study. J. Am. Med. Ass. 1992;267:253–258
  7. Dickersin K, Berlin JA. Meta-analysis: state-of-the science. Epidemiol. Rev. 1992;14:154–176
  8. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. J. Am. Med. Ass. 1965;193:80–84
  9. Farrell M, Ward UJ, Mattick R, Hall W, Stimson G, des Jarlais D, et al.  Methadone maintenance treatment in opiate dependence: a review. Br. Med. J. 1994;309:971–1001
  10. Fudala PJ, Jaffe JH, Dax EM, Johson RE. Use of buprenorphine in the treatment of opioid addiction, II: physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin. Pharmacol. Ther. 1990;47:525–534
  11. General Accounting Office. 1990, Methadone Maintenance: some treatment programmes are not effective; greater federal oversight needed GAO/HRD-90-104.
  12. Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. Am. J. Addict. 1997;4:339–349
  13. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 2000;58:55–66
  14. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin. Trials. 1996;17:1–12
  15. Jaffe JH, Senay EC, Schuster CR, Renault PR, Smith B, DiMenza S. Methadyl acetate vs methadone. J. Am. Med. Ass. 1972;222:437–442
  16. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New Engl. J. Med. 2000;343:1290–1297
  17. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 1995;40:27–35
  18. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. J. Am. Med. Ass. 1992;267:2750–2755
  19. Jones HE, Strain EC, Bigelow GE, Walsh SL, Stitzer ML, Eissenberg T, et al.  Induction with levomethadyl acetate: safety and efficacy. Archs. Gen. Psychiat. 1998;55:729–736
  20. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 1993;181:358–364
  21. Kuhlman JJ, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 1998;93:549–559
  22. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, et al.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–486
  23. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A Veterans Administration Cooperative Study. Archs. Gen. Psychiat. 1976;33:709–720
  24. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archs. Gen. Psychiat. 1996;53:401–407
  25. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515–532
  26. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. J. Am. Med. Ass. 1993;269:1953–1959
  27. Nath RP, Upton RA, Everhart T, Cheung P, Shwonek P, Jones RT, et al.  Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulation. J. Clin. Pharmacol. 1999;39:619–623
  28. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–488
  29. Normand ST. Meta-analysis: formulating, evaluating, combining and reporting. Stat. Med. 1999;18:321–359
  30. Panell J, Charuvastra VC, Ouren J. Methadyl acetate versus methadone: the experience of one hospital. Med. J. Aust. 1977;2:150–152
  31. Pernerger TV, Giner FS, del Rı́o M, Mino A. Randomized trial of heroin maintenance programme for addicts who fail in conventional drug treatments. Br. Med. J. 1998;317:13–18
  32. Rawson RA, Hasson AL, Huber AM, McCann MJ, Ling W. A 3-year progress report on the implementation of LAAM in the United States. Addiction. 1998;93:533–540
  33. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998;93:1385–1392
  34. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. New Engl. J. Med. 1987;316:450–455
  35. San L, Camı́ J, Fernández T, Ollé JM, Peri JM, Torrens M. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. Br. J. Addict. 1992;87:55–62
  36. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archs. Gen. Psychiat. 1997;54:713–720
  37. Stine SM, Kosten TR. Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. Am. J. Drug Alcohol Abuse. 1994;20:445–458
  38. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence. J. Am. Med. Ass. 1999;281:1000–1005
  39. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann. Intern. Med. 1993;119:23–27
  40. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol. Depend. 1993;33:105–117
  41. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology. 1994;116:401–406
  42. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiat. 1994;151:1025–1030
  43. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J. Clin. Psychopharmacol. 1996;16:58–67
  44. Strang J, Sheridan J. Effects of government recommendations on methadone prescribing in South and East England: comparison of 1995 and 1997 surveys. Br. Med. J. 1998;317:1489–1490
  45. Tignol J, Auriacombe M, Daulouède JP. Buprenorphine treatment for heroin addiction. Int. J. Psychopharmacol. 1998;1(Suppl. 1):S39–S40
  46. Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L. Methadone and quality of life (Letter). Lancet. 1999;353:1101
  47. Torrens M, San L, Martı́nez A, Castillo C, Domingo-Salvany A, Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction. 1997;92:707–716
  48. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 1998;22:430–434
  49. Tracqui A, Tournoud C, Flesh F, Kopferschmitt J, Kintz P, Deveaux M, et al.  Acute poisoning during substitution therapy based on high-dose buprenorphine. 29 clinical cases — 20 fatal cases (English abstract). Presse Med. 1998;27:557–561
  50. Turner RM, Omar RZ, Yany M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat. Med. 2000;19:3417–3432
  51. Walsh SL, Johnson RE, Cone EJ, Bigelow GE. Intravenous and oral l-alfa-aceylmethadol: pharmacodynamics and pharmacokinetics in humans. J. Pharmacol. Exp. Ther. 1998;285:71–82
  52. Walsh SL, Preston KI, Stitzer MI, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 1994;55:569–580
  53. Walter SD. Methods of reporting statistical results from medical research studies. Am. J. Epidemiol. 1995;141:896–906
  54. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–226

PII: S0376-8716(01)00171-5

doi: 10.1016/S0376-8716(01)00171-5

Drug and Alcohol Dependence
Volume 65, Issue 3 , Pages 283-290 , 1 February 2002

Article Tools

* Image Usage & Resolution